Table 1.

Change in %MD for continued use and hormone therapy cessation groups by demographic and reproductive factors

Continued use groupHormone therapy cessation group
 Median change in %MD (95% CI)NOutcome: %MD change: row percentMedian change in %MD (95% CI)NOutcome: %MD change: row percent
DecreaseNo change ±3%Increase >3%DecreaseNo change ±3%Increase >3%
≥7.5%>3% to <7.5%≥7.5%>3% to <7.5%
Overall−0.7 (−1.3 to −0.2)43015203629−2.4 (−2.7 to −1.4)73821243223
Age, y
 45–55−0.6 (−1.8 to 0.5)11617173530−3.4 (−4.4 to −2.4)19926252820
 56–65−0.8 (−1.8 to 0.6)21415213529−1.7 (−2.6 to −0.7)38118243225
 66+−0.6 (−1.9 to 0.9)10013213927−1.4 (−3.1 to −0.3)15819243621
Caucasian
 No−0.2 (−3.0 to 3.1)31161632350.7 (−2.2 to 3.0)7017202439
 Yes−0.8 (−1.4 to −0.2)39815213628−2.4 (−3.0 to −1.7)66421253322
Baseline BMI, kg/m2
 <25−0.2 (−1.4 to 1.0)19117153434−1.6 (−2.6 to −0.3)31120223127
 25–30−0.7 (−1.7 to −0.1)14712233926−2.0 (−3.0 to −0.7)24420243224
 >30−1.4 (−3.5 to 0.05)9217253523−3.4 (−4.4 to −2.0)18322293316
Baseline %MD
 10% to <20%−0.3 (−1.4 to 0.6)1374215026−0.8 (−1.8 to 0.3)2419274024
 20% to <30%0.2 (−1.0 to 2.0)11912193435−1.7 (−2.5 to −0.6)20117243623
 30% to <40%−2.6 (−4.4 to −0.1)8725232625−3.4 (−4.8 to −2.0)15228252620
 40+%−2.6 (−4.9 to −0.3)8729162629−5.1 (−7.0 to −2.7)14438201824
Parity
 Parous−0.9 (−1.5 to −0.2)34716203627−2.3 (−2.9 to −1.5)58321253223
 Nulliparous−0.2 (−1.1 to 1.8)8212183534−1.5 (-3.2 to −0.3)15320243324
Family history of breast cancer (first degree)
 No−0.4 (−0.9 to 0.2)33016183630−2.3 (−3.0 to −1.5)58921243123
 Yes−2.2 (−3.4 to −0.4)8912303126−1.7 (−3.2 to −0.5)13019243522
Change in BMI, kg/m2
 Decrease >1.51.1 (−3.4 to 4.3)3711243035−0.9 (−3.6 to 0.2)6416233823
 No change (≤1.5)−0.4 (−1.4 to 0.4)28616183531−2.0 (−2.6 to −1.1)48621243026
 Increase >1.5−1.8 (−3.5 to −0.7)8417243920−2.9 (−4.1 to −1.7)15922273318
Hormone therapy type
 Estrogen therapy−0.9 (−1.7 to −0.2)26416223527−2.1 (−2.7 to −1.1)45019253323
 Estrogen + progesterone−0.2 (−1.4 to 0.8)16614163732−2.4 (−3.4 to −1.2)28824243023
Duration of prior hormone therapy use at baseline, y
 <50.5 (−1.1 to −2.5)5716143733−1.7 (−5.1 to 1.7)8631132431
 5–9−1.2 (−2.8 to 0.5)9318183528−2.7 (−3.9 to −1.6)15923253517
 10–14−0.7 (−1.8 to 2.0)8314202936−2.2 (−3.5 to −1.0)16717283223
 15+−0.9 (−1.6 to 0.2)17314223825−2.0 (−3.1 to −0.6)27720253322

NOTE: Row percents may not add to 100 because of rounding to the nearest 1%. N's may not sum to totals due to missing values. The study had 88% power to detect a 7% change in density among exposed women, if there were no change among unexposed.